

REPLACE and IMPACT RCTs demonstrate the FreeStyle Libre system achieves significant reductions in hypoglycaemia compared to SMBG^{1,2,3,4}

Mean reductions in hypoglycaemia* with FreeStyle Libre system compared with SMBG per patient per 24hr day (change from baseline to 6 months)

T2DM - REPLACE



T1DM - IMPACT



SMBG = self-monitoring of blood glucose; T1DM = type 1 diabetes mellitus; T2DM = type 2 diabetes mellitus

* Hypoglycaemia sensor-defined as <3.9mmol/L (<70mg/dL).

** Adjusted difference versus SMBG.

1. Data on file, Abbott Diabetes Care. An Evaluation of a Novel Glucose Sensing Technology in Type 1 Diabetes (IMPACT). [Clinical Trial Identifier: NCT02232698].

2. Data on file, Abbott Diabetes Care. An Evaluation of a Novel Glucose sensing Technology in Type 2 Diabetes (REPLACE). [Clinical Trial Identifier: NCT02082184].

3. Haak T et al. Diabetes Technol Ther 2016;18(Suppl 1):A28.

4. Bolinder J et al. Diabetes 2016;65(Suppl 1):A222.